
美沙拉嗪PEG化前药在不同种属血浆中蛋白结合率的测定
Determination of protein binding rate of mesalazine-PEG prodrug in plasma from different species
目的:测定美沙拉嗪PEG化前药在不同种属血浆中的蛋白结合率,考察PEG化对药物蛋白结合率的影响。方法:采用血浆平衡透析法,以紫外分光光度法对透析内液与外液中的药物含量进行测定,计算药物与小鼠血浆、犬血浆、兔血浆及牛血浆的蛋白结合率。结果:美沙拉嗪PEG化物的低、中、高(1.08,1.35,1.62 mg·mL-1)3种质量浓度的小鼠血浆蛋白结合率分别为(22.31±5.28)%,(17.15±3.21)%,(16.11±4.55)%;犬血浆为(25.16±5.87)%,(22.47±4.14)%,(23.14±3.46)%;兔血浆为(17.13±8.26)%,(13.87±6.32)%,(15.93±2.31)%;牛血浆为(14.41±6.21)%,(18.84±7.80)%,(14.18±5.23)%。结论:美沙拉嗪PEG化物血浆蛋白结合程度较低,种属间存在一定差异。与原型药物相比,药物经PEG化后,血浆蛋白结合呈下降趋势。
OBJECTIVE To determine protein binding rates of mesalazine-PEG prodrug in plasma from different species, and to examine impacts of PEGylation on plasma protein binding rates.METHODS Equilibrium dialysis method was carried out to determine plasma protein binding rates in mouse plasma, dog plasma, rabbit plasma and bovine plasma. Ultraviolet spectrophotometry was employed to determine concentration of drugs inside or outsides of dialysis membrane, and then protein binding rate was calculated.RESULTS Plasma protein binding rates of mesalazine-PEG conjugates at low, middle and high concentrations in different species were as follows. Plasma protein binding rates were (22.31±5.28)%, (17.15±3.21)%, (16.11±4.55)% in mouse plasma, (25.16±5.87)%, (22.47±4.14)%, (23.14±3.46)% in dog plasma, (17.13±8.26)%, (13.87±6.32)%, (15.93±2.31)% in rabbit plasma, and (14.41±6.21)%, (18.84±7.80)%, (14.18±5.23)% in bovine plasma, respectively.CONCLUSION Plasma protein binding of mesalazine-PEG conjugates is at low strength and there are some differences between species. Compared with prototype drugs, plasma protein binding rates of mesalazine-PEG conjugates tend to decrease after PEGylation.
美沙拉嗪 / PEG化 / 蛋白结合率 / 平衡透析法 / 种属差异 {{custom_keyword}} /
mesalazine / PEGylation / plasma protein binding rate / equilibrium dialysis / specy differences {{custom_keyword}} /
[1] Zhou Qing-song, Jiang Xue-hua, Li Ke-jia, et al. Synthesis,characterization and in situ intestinal absorption of different molecular weight scutellarin-PEG conjugates[J]. Pharmazie, 2006, 61(8):660-663.
[2] Greenwald RB, Choe YH, Mcguire J, et al. Effective drug delivery by PEGylated drug conjugates[J]. Adv Drug Deliv Revi, 2003, 55(2):217-250.
[3] 张弘,张晖芬,常会超,等.齐墩果酸在人血浆蛋白和血清白蛋白中结合率的测定[J].药学学报,2011,46(2):243-246.
[4] 中国药典.二部[S]. 2010:附录30-31.
[5] 景春杰,陈晓辉,刘璇,等.丹酚酸B与大鼠血浆蛋白结合率的测定[J].药学学报,2010,45(3):343-346.
[6] 刘颖,陈志强,陶蓓蕾,等.蟾毒灵血浆蛋白结合率的测定[J].中国中药杂志,2009,34(21):2817-2820.
[7] Kariv I, Hong Cao, Oldenburg KR. Development of a high throughput equilibrium dialysis method[J]. J Pharm Sci, 2001, 90(5):580-587.
[8] 高秀蓉,蒋学华,王婷.HPLC法测定蝙蝠葛碱与大鼠和人血浆蛋白的结合率[J].中国药房,2011(31):2894-2897.
[9] 杜英峰,靳怡然,许慧君,等.冬凌草甲素在不同种属血浆中蛋白结合率的HPLC法测定[J].药物分析杂志,2012,03(3):383-387.
[10] Gleeson MP. Plasma protein binding affinity and its relationship to molecular structure:an in-silico analysis[J]. J Med Chem, 2007, 50(1):101-112.
国家自然科学基金项目(编号:81160397);江西省自然科学基金项目(编号:20114BAB205031)
/
〈 |
|
〉 |